UCI Investigates Synthetic Vasoactive Intestinal Polypeptide-based Experimental Drug on High Risk SARS-CoV-2 Patients

UCI Investigates Synthetic Vasoactive Intestinal Polypeptide-based Experimental Drug on High Risk SARS-CoV-2 Patients

University of California Irvine, (UCI) recently announced their participation in a COVID-19-focused clinical trial investigating a drug called Aviptadil in at risk patients. Dr. Richard Lee, Interim chief of UCK Health Division of Pulmonary Diseases and Critical Care...
The FDA Approving Experimental Stem Cell Therapies Targeting Patients with Severe COVID-19 Cases

The FDA Approving Experimental Stem Cell Therapies Targeting Patients with Severe COVID-19 Cases

Novel medical innovations are being pursued by biotech companies and clinical investigators to halt COVID-19 causalities as there is, presently, no approved treatment for the novel coronavirus—especially in severe, escalated conditions where mortality is more...

Pin It on Pinterest